Claims

1. A compound of formula (I):



(I)

wherein

R^1 is 9- or 10-membered bicyclic heteroaryl wherein the 9- or 10-membered bicyclic heteroaryl contains from one to three heteroatoms independently selected from oxygen and nitrogen and is optionally substituted by C_{1-6}alkyl, C_{3-6}cycloalkyl, halo, -CN or -$NHSO_2R^5$, or

pyridinyl optionally substituted by one or two substituents independently selected from C_{1-6}alkyl, -OR^6, halo and -$NHSO_2R^7$;

R^2 and R^3, together with the nitrogen atom to which they are attached, are linked to form a 6- or 7-membered heterocyclyl wherein the 6- or 7-membered heterocyclyl optionally contains an oxygen atom or a further nitrogen atom and is optionally substituted by one or two substituents independently selected from C_{1-6}alkyl;

R^4 is hydrogen or methyl;

R^6 is hydrogen or C_{1-4}alkyl; and

R^5 and R^7 are each independently C_{1-6}alkyl, or phenyl optionally substituted by one or two substituents independently selected from halo;

or a salt thereof.

2. A compound according to claim 1, or a salt thereof, wherein R^1 is 9-membered bicyclic heteroaryl wherein the 9-membered bicyclic heteroaryl contains one or two nitrogen atoms, or pyridinyl optionally substituted by one or two substituents independently selected from $-OR^6$ and $-NHSO_2R^7$.

3. A compound according to claim 1 or claim 2, or a salt thereof, wherein R^1 is indolyl.

4. A compound according to claim 1 or claim 2, or a salt thereof, wherein R^1 is pyridinyl optionally substituted by one or two substituents independently selected from $-OR^6$ and $-NHSO_2R^7$.

5. A compound according to any one of the preceding claims, or a salt thereof, wherein R^2 and R^3, together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl wherein the 6-membered heterocyclyl optionally contains an oxygen atom or a further nitrogen atom and is optionally substituted by one or two substituents independently selected from C_{1-6}alkyl.

6. A compound according to any one of the preceding claims, or a salt thereof, wherein R^2 and R^3, together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl wherein the 6-membered heterocyclyl contains an oxygen atom and is optionally substituted by one or two substituents independently selected from C_{1-4}alkyl.

7. A compound according to any one of claims 1 to 5, or a salt thereof, wherein R^2 and R^3, together with the nitrogen atom to which they are attached, are linked to form a 6-membered heterocyclyl wherein the 6-membered heterocyclyl contains a further nitrogen atom and is optionally substituted by C_{1-4}alkyl.

8. A compound according to any one of the preceding claims, or a salt thereof, wherein R^4 is hydrogen.

9. A compound which is:
N-[5-[4-(5-{[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide;
N-[5-[4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide;

N-[5-[4-(5-{[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]-2,4-difluorobenzenesulfonamide;

2,4-difluoro-*N*-[5-[4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]benzenesulfonamide;

4-(5-{[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-6-(1*H*-indol-4-yl)-1*H*-indazole;

6-(1*H*-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazole;

6-(1*H*-indol-4-yl)-4-[5-(4-morpholinylmethyl)-1,3-oxazol-2-yl]-1*H*-indazole;


N-[5-[4-(5-{[(2*R*,6*R*)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide;

6-(1*H*-indol-4-yl)-4-[5-(1-piperazinylmethyl)-1,3-oxazol-2-yl]-1*H*-indazole; or

a salt thereof.

10. A compound which is:


N-[5-[4-(5-{[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide



; or a salt thereof.

11. A compound which is:


6-(1*H*-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazole




; or a salt thereof.

12. A compound according to any one of claims 1 to 11 in the form of a pharmaceutically acceptable salt thereof.

13. *N*-[5-[4-(5-{[(2*R*,6*S*)-2,6-Dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide



14. 6-(1*H*-Indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazole



15. A pharmaceutical composition comprising a compound as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

16. A pharmaceutical composition comprising *N*-[5-[4-(5-{[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

17. A pharmaceutical composition comprising 6-(1*H*-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazole or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

18. A compound as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in medical therapy.

19. *N*-[5-[4-(5-{[(2*R*,6*S*)-2,6-Dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide or a pharmaceutically acceptable salt thereof for use in medical therapy.

20. 6-(1*H*-Indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazole or a pharmaceutically acceptable salt thereof for use in medical therapy.

21. A compound as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity.

22. *N*-[5-[4-(5-{[(2*R*,6*S*)-2,6-Dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide or a pharmaceutically acceptable salt thereof for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity.

23. 6-(1*H*-Indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazole or a pharmaceutically acceptable salt thereof for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity.

24. Use of a compound as defined in any one of claims 1 to 11, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity.

25. Use of *N*-[5-[4-(5-{[(2*R*,6*S*)-2,6-dimethyl-4-morpholinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazol-6-yl]-2-(methyloxy)-3-pyridinyl]methanesulfonamide or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity.

26. Use of 6-(1*H*-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1*H*-indazole or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity.

27. A compound for use according to any one of claims 21 to 23 wherein the disorder mediated by inappropriate PI3-kinase activity is a respiratory disease, a viral infection, a non-viral respiratory infection, an allergic disease, an autoimmune disease, an inflammatory disorder, a cardiovascular disease, a hematologic malignancy, a neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, or pain.


28. A compound for use according to any one of claims 21 to 23 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), viral respiratory tract infections, viral exacerbation of respiratory diseases, aspergillosis, leishmaniasis, allergic rhinitis, atopic dermatitis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, thrombosis, atherosclerosis, hematologic malignancy, neurodegenerative disease, pancreatitis, multiorgan failure, kidney disease, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection, lung injury, pain associated with rheumatoid arthritis or osteoarthritis, back pain, general inflammatory pain, post hepatic neuralgia, diabetic neuropathy, inflammatory neuropathic pain (trauma), trigeminal neuralgia or Central pain.

29. A compound for use according to any one of claims 21 to 23 wherein the disorder mediated by inappropriate PI3-kinase activity is asthma.

30. A compound for use according to any one of claims 21 to 23 wherein the disorder mediated by inappropriate PI3-kinase activity is COPD.

CLAIMS


1. 6-(1H-Indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-indazole




or a salt thereof.

2. A compound according to claim 1 in the form of a pharmaceutically acceptable salt thereof.

3. 6-(1H-Indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hydrochloride



4. 6-(1H-Indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole



5. A pharmaceutical composition comprising a compound as claimed in claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable excipients.

6. A pharmaceutical composition comprising 6-(1H-indol-4-yl)-4-(5-{[4-(1-methylethyl)-1-piperazinyl]methyl}-1,3-oxazol-2-yl)-1H-indazole hydrochloride, and one or more pharmaceutically acceptable excipients.

7. The compound according to claim 1, wherein said compound is present in the form of a succinate salt.

8. A pharmaceutical compostion comprising the compound according to claim 7, and one or more pharmaceutically acceptable excipients.